Product image of Olmesartán/Amlodipino Stada (Olmesartan Medoxomil, Amlodipine) supplied by GNH India

Olmesartán/Amlodipino Stada

Active Ingredient:
Olmesartan Medoxomil, Amlodipine
Origin:
EU

Olmesartán/Amlodipino Stada (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartán/Amlodipino Stada, is an angiotensin II receptor blocker (ARB) presented as a oral tablet for systemic use. It treats hypertension and may be used in adults requiring blood pressure control.

GNH India supplies Olmesartán/Amlodipino Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratorio Stada, S.L.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmesartan medoxil combined with amlodipine is indicated for hypertension management, targeting the renin‑angiotensin system and calcium‑channel pathways.

  • Hypertension: improves blood pressure control when monotherapy is insufficient.
  • High‑risk cardiovascular patients: reduces the risk of stroke and myocardial infarction as part of a comprehensive regimen.
  • Elderly patients with systolic hypertension: provides effective BP lowering with a favorable tolerability profile.

How It Works

  • Olmesartan medoxil selectively blocks the AT1 subtype of angiotensin II receptors, preventing vasoconstriction and aldosterone release. Amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combination produces additive blood‑pressure‑lowering effects through complementary inhibition of the renin‑angiotensin system and calcium‑mediated vasoconstriction.

Side Effects

Adverse reactions reported with the olmesartan/amlodipine combination are generally dose‑related and may vary in frequency.

Common Side Effects

  • Peripheral edema: swelling of the lower limbs.
  • Dizziness or light‑headedness: especially after the first doses.
  • Headache: mild to moderate intensity.
  • Flushing: transient warmth and redness.
  • Fatigue: general sense of tiredness.
  • Nausea: occasional stomach upset.

Serious or Rare Side Effects

  • Angio‑edema: rapid swelling of face, lips or throat.
  • Severe hypotension: symptomatic low blood pressure.
  • Hepatic dysfunction: elevated liver enzymes.
  • Renal impairment: worsening kidney function.
  • Cardiac arrhythmias: irregular heart rhythms.
  • Allergic reactions: rash, pruritus, or anaphylaxis.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient history and monitor relevant parameters.

  • Renal function: assess baseline creatinine and eGFR.
  • Hepatic function: check liver enzymes in patients with liver disease.
  • Electrolytes: monitor potassium levels, especially if combined with potassium‑sparing diuretics.
  • Pregnancy: avoid use; teratogenic risk is associated with ARBs.
  • Concomitant antihypertensives: adjust dose to prevent excessive hypotension.
  • Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Olmesartan/amlodipine may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid)

  • Dual renin‑angiotensin system blockade: combining with ACE inhibitors or other ARBs can increase risk of renal dysfunction and hyperkalaemia.
  • Potassium‑rich supplements or potassium‑sparing diuretics: may cause dangerous hyperkalaemia.
  • Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine plasma levels.

Moderate Interactions (Monitor Closely)

  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
  • Diuretics: may enhance hypotensive response, requiring dose adjustment.
  • Lithium: concurrent use can increase lithium concentrations.
  • Antidiabetic agents: blood‑glucose control may improve, risking hypoglycaemia.
  • Alcohol: additive vasodilatory effect may increase dizziness.

Frequently Asked Questions

Olmesartán/Amlodipino Stada is a fixed‑dose combination of olmesartan medoxil and amlodipine used to treat high blood pressure, especially when a single agent does not achieve target levels. It is prescribed for adults with essential hypertension and may be part of a broader cardiovascular risk‑reduction strategy.

Olmesartan medoxil blocks AT1 angiotensin II receptors, preventing vasoconstriction and aldosterone‑mediated sodium retention. This action lowers systemic vascular resistance and blood pressure. When combined with amlodipine, which relaxes arterial smooth muscle by inhibiting calcium influx, the two agents provide complementary blood‑pressure reduction.

The appropriate dose is determined by the prescribing clinician based on the patient’s blood‑pressure readings, comorbidities, and response to therapy. Dosage adjustments are made individually; patients should follow the prescriber’s instructions and not alter the regimen without medical advice.

Olmesartan, an ARB, is contraindicated in pregnancy because of potential fetal toxicity, including renal dysfunction and skull hypoplasia. Breastfeeding is not recommended as the drug may pass into milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternative antihypertensive options with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Compared with monotherapy, the olmesartan‑amlodipine combo offers additive blood‑pressure reduction, often achieving targets with fewer tablets. It may be preferred over separate prescriptions for convenience and adherence. Relative to other ARB‑calcium‑channel combinations, efficacy and tolerability are similar, though individual patient response can vary.

Store the tablets at temperatures below 25 °C in their original packaging. Protect them from moisture, excessive heat and direct sunlight to maintain potency throughout the shelf‑life.

The product is taken orally, usually once daily, with or without food. Patients should swallow the tablet whole with a glass of water and follow the dosing schedule prescribed by their clinician.

Serious adverse events include angio‑edema, severe hypotension, significant renal impairment, and hepatic dysfunction. Patients should seek immediate medical attention if they experience swelling of the face or throat, dizziness, fainting, or signs of liver injury such as jaundice.

Individuals with known hypersensitivity to olmesartan, amlodipine or any tablet excipients should avoid the product. It is also contraindicated in pregnancy, and caution is advised for patients with severe hepatic or renal impairment, or those on interacting medications such as other ARBs, ACE inhibitors or potassium‑sparing diuretics.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT